ANEB — Anebulo Pharmaceuticals, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1815974 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -2,067,334 | -1,999,397 | 9,421,997 | 9,041,570 | 1,485,646 |
| Sep 2025 | 0 | — | -2,250,435 | -2,158,354 | 10,701,039 | 10,354,773 | 963,821 |
| Jun 2025 | 0 | — | -2,249,541 | -2,144,828 | 12,145,616 | 11,627,849 | 487,688 |
| Mar 2025 | 0 | — | -1,532,716 | -1,676,169 | 14,008,484 | 13,279,901 | 546,032 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,840,233
Investing CF
—
Financing CF
$-116,664
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.19
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-78,046,258
Inventory
—
Receivables
$56,783
ST Investments
—
EBIT TTM
$-7,681,249
Pretax Income TTM
$-7,978,748
Interest Exp TTM
$297,499
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -8,359,467 | -8,484,763 | 12,145,616 | 487,688 | — | -6,349,687 |
| Jun 2024 | 0 | -8,308,755 | -8,201,703 | 4,073,114 | 260,583 | — | -8,090,849 |
| Jun 2023 | 0 | -11,783,599 | -11,732,338 | 11,670,151 | 1,068,801 | — | -9,683,133 |
| Jun 2022 | 0 | -6,831,174 | -6,825,619 | 15,579,431 | 512,531 | — | -5,437,174 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.65
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.11T | $1246.93 | — |
| JNJ | JOHNSON & JOHNSON | $658.00B | $273.04 | — |
| ABBV | AbbVie Inc. | $467.44B | $264.52 | — |
| MRK | Merck & Co., Inc. | $371.70B | $150.66 | — |
| NVSEF | NOVARTIS AG | $310.96B | $163.60 | — |
News headlines (Yahoo Finance, 1h cache)
We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely
2025-10-04 14:03 · Yahoo
Anebulo begins Phase I trial of IV cannabis antidote
2025-09-26 09:24 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.